Share

September 2021; 8 (5) ArticleOpen Access

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19

Leoni Rolfes, Marc Pawlitzki, Steffen Pfeuffer, Christopher Nelke, Anke Lux, Refik Pul, Christoph Kleinschnitz, Konstanze Kleinschnitz, Rebeca Rogall, Katrin Pape, Stefan Bittner, Frauke Zipp, Clemens Warnke, Yasemin Goereci, Michael Schroeter, Jens Ingwersen, Orhan Aktas, Luisa Klotz, Tobias Ruck, Heinz Wiendl, Sven G. Meuth
First published July 14, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001035
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1954

Share

Article Information

vol. 8 no. 5 e1035
DOI: 
https://doi.org/10.1212/NXI.0000000000001035
PubMed: 
34261812
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received February 1, 2021
  • Accepted in final form April 22, 2021
  • First Published July 14, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Leoni Rolfes, MD (leoni.rolfes{at}ukmuenster.de)*,
    2. Marc Pawlitzki, MD (marc.pawlitzki{at}ukmuenster.de)*,
    3. Steffen Pfeuffer, MD (steffen.pfeuffer{at}ukmuenster.de),
    4. Christopher Nelke, MD (christopher.nelke{at}ukmuenster.de),
    5. Anke Lux (anke.lux{at}med.ovgu.de),
    6. Refik Pul, MD (refik.pul{at}uk-essen.de),
    7. Christoph Kleinschnitz, MD (christoph.kleinschnitz{at}uk-essen.de),
    8. Konstanze Kleinschnitz, PhD (konstanzekleinschnitz{at}hotmail.com),
    9. Rebeca Rogall, MD (rebecca.rogall{at}gmx.de),
    10. Katrin Pape, MD (katrin.pape{at}unimedizin-mainz.de),
    11. Stefan Bittner, MD (bittner{at}uni-mainz.de),
    12. Frauke Zipp, MD (zipp{at}uni-mainz.de),
    13. Clemens Warnke, MD (clemens.warnke{at}uk-koeln.de),
    14. Yasemin Goereci, MD (yasemin.goereci{at}uk-koeln.de),
    15. Michael Schroeter, MD (michael.schroeter{at}uk-koeln.de),
    16. Jens Ingwersen, MD (jens.ingwersen{at}uni-duesseldorf.de),
    17. Orhan Aktas, MD (orhan.aktas{at}med.uni-duesseldorf.de),
    18. Luisa Klotz, MD (luisa.klotz{at}ukmuenster.de),
    19. Tobias Ruck, MD (tobias.ruck{at}med.uni-duesseldorf.de),
    20. Heinz Wiendl, MD (heinz.wiendl{at}ukmuenster.de) and
    21. Sven G. Meuth, MD
  1. Leoni Rolfes, MD (leoni.rolfes{at}ukmuenster.de)*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Merck Serono, travel reimbursements (2) Sanofi Genzyme, travel reimbursements

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Marc Pawlitzki, MD (marc.pawlitzki{at}ukmuenster.de)*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Novartis, funding for travel to conference 2014-2016 Merck Serono, funding for travel to conference 2017

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Steffen Pfeuffer, MD (steffen.pfeuffer{at}ukmuenster.de),
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Commercial entity: Travel grants by Sanofi Genzyme, Merck, Biogen, Mylan

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Commercial entity: Research support from DIAMED and Merck Serono

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Society: Research support from the German Multiple Sclerosis Society (DMSG)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Christopher Nelke, MD (christopher.nelke{at}ukmuenster.de),
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. Dr. Nelke received research grants from the Innovative Medizinsche Forschung(IMF) Muenster.

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Anke Lux (anke.lux{at}med.ovgu.de),
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Refik Pul, MD (refik.pul{at}uk-essen.de),
    7. Scientific Advisory Boards:

    1. (1) Alexion (2) Biogen (3) Celgene (4) Merck (5) Mylan (6) Novartis (7) Roche (8) Sanofi

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Alexion, funding for travel to congress, speaker honoraria (2) Biogen, funding for travel to congress, speaker honararia (3) Celgene, funding for travel to congress, speaker honoraria (4) Merck, funding for travel to congress, funding for research, speaker honoraria (5) Mylan, speaker honararia (6) Novartis, funding for research, speaker honoraria (7) Roche, speaker honararia (8) Sanofi-Genzyme, speaker honoraria

    Editorial Boards:

    1. Guest Editor in Frontiers in Neurology Guest Editor in Cells

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Merck (2) Novartis

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Christoph Kleinschnitz, MD (christoph.kleinschnitz{at}uk-essen.de),
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Konstanze Kleinschnitz, PhD (konstanzekleinschnitz{at}hotmail.com),
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Rebeca Rogall, MD (rebecca.rogall{at}gmx.de),
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Merck, travel costs

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Katrin Pape, MD (katrin.pape{at}unimedizin-mainz.de),
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Stefan Bittner, MD (bittner{at}uni-mainz.de),
    12. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. S. B. has received funding for travel expenses for attending meetings from Novartis and Merck Serono and honoraria from Biogen Idec, BMS, Merck Serono, Novartis, Roche, Sanofi Genzyme and TEVA.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) German Research Council (DFG, CRC-TR-128)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Frauke Zipp, MD (zipp{at}uni-mainz.de),
    13. Scientific Advisory Boards:

    1. (1) Novartis (2) Octapharma (3) Merck Serono (4) ONO Pharma (5) Biogen (6) Genzyme (7) Celgene (8) Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis (2) Octapharma (3) Merck Serono (4) ONO Pharma (5) Biogen (6) Genzyme (7) Celgene (8) Roche

    Editorial Boards:

    1. (1) Brain, Associate Editor, 2021-

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Genzyme

    Research Support, Government Entities:

    1. (1) DFG CRC-TRR 128, Co-Spokesperson/Spokesperson, 2012-2024 (2) DFG CRC1080, PI, 2013-2024 (3) BMBF HaltMS, PI, 2020-2023

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Progressive MS Alliance, BRAVEinMS

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  13. Clemens Warnke, MD (clemens.warnke{at}uk-koeln.de),
    14. Scientific Advisory Boards:

    1. Biogen, Novartis, Roche, Janssen; institutional fees only.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speakers honoraria Novartis, Biogen, Bayer, Genzyme, Alexion. Institutional fees only.

    Editorial Boards:

    1. Frontiers in Neurology, associate editor, 2016-

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Speakers honoraria payed to the institution: Novartis, Biogen, Roche.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  14. Yasemin Goereci, MD (yasemin.goereci{at}uk-koeln.de),
    15. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  15. Michael Schroeter, MD (michael.schroeter{at}uk-koeln.de),
    16. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1)Astellas, speaker honorarium, (2)Bayer, speaker + travel honoraria, (3) Biogen Idecspeaker + travel honoraria, (4) Merck Serono speaker + travel honoraria, ( 5)Teva, speaker + travel honoraria, (6) Novartis Pharma, speaker honoraria, (7) Sanofi, speaker + travel honoraria.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis, (2) Bayer

    Research Support, Government Entities:

    1. (1)EU FP7 program #2780006, “NeuroFGL

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  16. Jens Ingwersen, MD (jens.ingwersen{at}uni-duesseldorf.de),
    17. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  17. Orhan Aktas, MD (orhan.aktas{at}med.uni-duesseldorf.de),
    18. Scientific Advisory Boards:

    1. (1) Medimmune Scientific Advisory Board

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Bayer, speaker honoraria (2) Novartis, speaker honoraria (3) Biogen, travel and speaker honoraria (4) Merck Serono, travel and speaker honoraria (5) Teva, speaker honoraria (6) Sanofi-Genzyme, speaker honoraria (7) Roche, travel and speaker honoraria (8) Almirall, speaker honoraria (9) Alexion, travel and speaker honoraria (10) Celgene, travel and speaker honoraria

    Editorial Boards:

    1. (1) PLoS ONE, Academic Editor, since 2012

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis

    Research Support, Government Entities:

    1. (1) German Ministry of Science (BMBF), PI for NationNMO/KKNMS (NationNMO‐PAT FKZ 01GI1602B), since 2016

    Research Support, Academic Entities:

    1. (1) German Research Foundation (DFG), PI in GRK2578, since 2020

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  18. Luisa Klotz, MD (luisa.klotz{at}ukmuenster.de),
    19. Scientific Advisory Boards:

    1. (1) Genzyme (2) Novartis (3) Roche (4) Merck (5) Janssen (6) Alexion

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis, speaker honoraria and travel support (2) Merck Serono, speaker honoraria and travel support (3) Biogen, speaker honoraria and travel support (4) Roche, speaker honoraria and travel support (5) Genzyme, speaker honoraria and travel support (6) Teva, speaker honoraria and travel support (7) Janssen, speaker honoraria and travel support (8) Santhera, speaker honoraria and travel support (9) Grifols, speaker honoraria and travel support (10)Alexion, speaker honoraria and travel support (11)Bayer, speaker honoraria and travel support

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis (2) Biogen (3) Merck (4) Immunic AG

    Research Support, Government Entities:

    1. (1) (CRC) SFB TR-128 Impact of dietary factors on the gut-CNS-axis – implications for CNS autoimmunity A08, Project leader, 2020-2024 (2) (CRC) SFB 1009 “Immune-cell interactions with endothelial cells and pericytes at the blood-brain- barrier: mechanisms and consequences” A03, Sub-project Leader, 2020-2024 (3) Interdisciplinary Centre for Clinical Research, Münster (IZKF),

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  19. Tobias Ruck, MD (tobias.ruck{at}med.uni-duesseldorf.de),
    20. Scientific Advisory Boards:

    1. TR has attended scientific advisory boards from Merck, Sanofi Aventis, Novartis, Alexion and Argenx.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. TR has received honoraria from Celgene/BMS, Biogen, Roche, Sanofi Aventis, Alexion, Novartis, and Teva

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. TR has received research support from Merck, Novartis and Sanofi Aventis.

    Research Support, Government Entities:

    1. TR has reveived funding from the German research foundation and the Federal Ministry of Education and Research - BMBF.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. TR has reveived funding from the Else Kröner Fresenius Foundation.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  20. Heinz Wiendl, MD (heinz.wiendl{at}ukmuenster.de) and
    21. Scientific Advisory Boards:

    1. (1) Biogen (2) Evgen (3) Genzyme (4) MedDay Pharmaceuticals (5) Merck Serono (5) Novartis (6) Roche Pharma AG (7) Sanofi-Aventis (8) UCB

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Alexion (2) Biogen (3) Cognomed (4) F. Hoffmann-La Roche Ltd. (5) Gemeinnützige Hertie-Stiftung (6) Merck Serono (7) Novartis (8) Roche Pharma AG (9) Sanofi-Genzyme (10) TEVA (11) WebMD Global

    Editorial Boards:

    1. (1) PLOS ONE, Editorial board member, since 2013 (2) Neurotherapeutics, since 2013 (3) Recent Patents on Inflammation & Allergy Drug Discovery

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Abbvie (2) Actelion (3) Argenx (4) Biogen (5) EMD (3) IGES (4) Johnson & Johnson (5) Merck (6) Novartis (7) Roche (8) Sanofi-Genzyme (9) Swiss Multiple Sclerosis Society (10)UCB

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biogen (2) GlaxoSmithKline GmbH (3) Roche Pharma AG (4) Sanofi-Genzyme

    Research Support, Government Entities:

    1. (1) German Ministry for Education and Research (BMBF), 01GI1601E, principal investigator, 2016-2019 (2)Interdisciplinary Centre of Clinical Research (IZKF) Muenster, principal investigator, 2015-2018 (4)PML Consortium, principal investigator, 2016-2018 (5) German Research Foundation, principal investigator,SFB 1009 TP A3 + SFB-TR CRC128 TP A09 + SFB TR CRC128 TP A10, TR CRC128 TP V, TR CRC128 TP Z02 2016- 2020

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Else Kröner Fresenius Foundation (2) Fresenius Foundation (3) Hertie Foundation (4) RE Children’s Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  21. Sven G. Meuth, MD
    22. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Sven G. Meuth received honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi- Aventis, Chugai Pharma, QuintilesIMS, and Teva.

    Editorial Boards:

    1. NONE

    Patents:

    1. Effectivity of specific FXII/FXIIa inhibitors, especially rHA-Infestin-4, in treating neuroinflammatory diseases (WO 2013/113774 A1 und EP 2 263 110 A1) Biomarkers for diagnosis and management of neuro- immunological diseases (WO 2016/028699 A2) NR2B selective NMDA-Receptor antagonists for treatment of immune-mediated inflammatory diseases (Reference number: PCT/EP2016/069975) Detection of anti-neurochondrin autoantibody in patients with cerebellar ataxia or cerebellitis (US10,112,982B2) Diagnosis of a novel autoimmune disease (EP086120B1; US2018/0298072,A1)

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. SGM's research is funded by Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva

    Research Support, Government Entities:

    1. SGM's research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), German Academic Exchange Service, Interdisciplinary Center for Clinical Studies (IZKF) Muenster

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. SGM's research is funded by the German Foundation Neurology, Hertie Foundation, Else Kröner Fresenius Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology with Institute of Translational Neurology (L.R., M.P., S.P., C.N., L.K., H.W.), University Hospital Muenster, Germany; Institute for Biometrics and Bioinformatic (A.L.), Otto-von-Guericke University, Magdeburg, Germany; Department for Neurology (R.P., C.K., K.K., R.R.), University Hospital Essen, Germany; Focus Program Translational Neurosciences (FTN) and Immunology (FZI) (K.P., S.B., F.Z.), Rhine Main Neuroscience Network (rmn2), Department of Neurology, University Medical Center of the Johannes Gutenberg University Mainz, Germany; Department of Neurology (C.W., Y.G., M.S.), University Hospital Cologne, Germany; and Department of Neurology (J.I., O.A., T.R., S.G.M.), Heinrich-Heine University, Duesseldorf, Germany.
  1. Correspondence
    Dr. Meuth sven.meuth{at}uni-duesseldorf.de
View Full Text

Article usage

Article usage: July 2021 to August 2023

AbstractFullPdfSource
Jul 2021921145272Highwire
Aug 2021157752252Highwire
Sep 202113668164Highwire
Oct 202116405146Highwire
Nov 20211930186Highwire
Dec 202120224107Highwire
Jan 20224062286Highwire
Feb 20221823579Highwire
Mar 20221725987Highwire
Apr 20221218352Highwire
May 20221316255Highwire
Jun 20221814743Highwire
Jul 2022815440Highwire
Aug 20221419449Highwire
Sep 20222016346Highwire
Oct 20221616670Highwire
Nov 20222418244Highwire
Dec 20221612828Highwire
Jan 20231613135Highwire
Feb 202379131Highwire
Mar 20231012035Highwire
Apr 2023278741Highwire
May 2023129127Highwire
Jun 202336526Highwire
Jul 202396823Highwire
Aug 202347930Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles